Clinical Trial Update: PICAROS - Acalabrutinib RWE on 1L CLL in Spain

View source ↗

Summary

The PICAROS study evaluating acalabrutinib for first-line chronic lymphocytic leukemia in Spain is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia | Status: ACTIVE_NOT_RECRUITING